This Week in Pulmonary — Jul 31, 2026

Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning major advances in chronic airway disease management, diagnostic innovations in oncology and infections, and critical updates in pulmonary fibrosis and mechanical ventilation. Let's dive in.

We begin with critical new insights into chronic airway diseases, where recent data challenge how we risk-stratify and manage our patients. In a prospective multicenter cohort study published in Chest, researchers analyzed data from 1,551 patients in the Korean COPD Subgroup Study to validate the Global Initiative for Chronic Obstructive Lung Disease 2026 strategy [5]. The updated 2026 guidelines lowered the threshold for high-risk classification, placing patients with just a single moderate exacerbation into the high-risk Group E. Over a 12-year follow-up, the investigators found that a single moderate exacerbation in the first year was independently associated with more than double the risk of future moderate-to-severe exacerbations, with an adjusted incidence rate ratio of 2.42, and more than triple the risk of respiratory mortality, with an adjusted hazard ratio of 3.21. Crucially, the 2026 classification demonstrated significantly better 10-year discrimination for all-cause mortality compared to the 2025 criteria, with an area under the curve of 0.760 versus 0.734. This structural-functional link is further emphasized by another study in Chest, which evaluated 5,276 adults undergoing low-dose computed tomography and spirometry over a median of nearly 13 years [9]. While low-level emphysema alone or obstructive lung disease alone did not significantly increase mortality, the combination of low-level emphysema and obstructive lung disease more than tripled the risk of death, yielding a hazard ratio of 3.10. Even among patients starting with very low emphysema, progression to higher levels increased mortality only in those with concurrent airflow limitation, with a hazard ratio of 3.97. Meanwhile, when it comes to managing exacerbations in these obstructive diseases, a randomized, double-blind, non-inferiority trial in Thorax investigated the safety of de-escalating maintenance macrolide therapy during the summer months [2]. Among 82 patients with asthma, chronic obstructive pulmonary disease, or bronchiectasis, the acute exacerbation rate was 50% in the de-escalation group compared to 33.3% in the continuation group. The risk difference of 16.2% failed to establish non-inferiority because the upper confidence limit exceeded the pre-specified 20% margin, and the median time to first exacerbation was more than halved in the de-escalation group, dropping from 206 days to just 90 days. This indicates that even during warmer seasons, stopping maintenance macrolides carries a substantial risk of early exacerbation recurrence.

Next, we turn to pulmonary fibrosis and respiratory infections. In the European Respiratory Journal, a pooled analysis of the FIBRONEER-IPF and FIBRONEER-ILD trials evaluated the oral phosphodiesterase 4B inhibitor nerandomilast [1]. Although the key secondary endpoint in the individual trials was not met, this pooled analysis of survival data over a mean of 16.7 months demonstrated that nerandomilast significantly improved survival. Compared to placebo, the 9 milligram twice-daily dose reduced the risk of death by 33%, with a hazard ratio of 0.67, while the 18 milligram twice-daily dose reduced the risk of death by 43%, with a hazard ratio of 0.57. Exposure-response analyses confirmed that higher plasma concentrations of the drug were linked to lower mortality, supporting the clinical use of the 18 milligram twice-daily regimen in patients with idiopathic and progressive pulmonary fibrosis. In the same journal, we also saw the publication of the FIBRO-COVID phase 2 randomized trial investigating the use of pirfenidone in post-COVID-19 pulmonary fibrosis [3], highlighting the ongoing interest in expanding antifibrotic therapies to non-idiopathic forms of lung injury. For patients with comorbid bronchiectasis and nontuberculous mycobacterial pulmonary disease, a large retrospective study in Chest evaluated over 2,600 patients across historical and contemporary cohorts [7]. The investigators found that as bronchiectasis severity increased, overall treatment success and culture conversion rates declined significantly, and the time to sputum conversion was prolonged. Moderate-to-severe bronchiectasis was an independent risk factor for treatment failure in patients with Mycobacterium abscessus, Mycobacterium intracellulare, and Mycobacterium avium, while only severe bronchiectasis compromised outcomes in Mycobacterium kansasii. To help clinicians navigate these and other complex lower respiratory tract infections, the European Respiratory Society and the European Society of Clinical Microbiology and Infectious Diseases published a state-of-the-science statement on rapid diagnostic tests [4]. The statement reviews the accuracy of these tests and their integration with biomarkers and clinical algorithms to optimize antibiotic stewardship and combat antimicrobial resistance.

In the field of thoracic oncology, diagnostic precision and streamlined triage remain paramount. A prospective multicenter study in Chest developed and validated a breathomics-based triage tool to distinguish lung cancer from benign mimics in patients with radiologically detected pulmonary abnormalities [6]. Analyzing exhaled volatile organic compounds using high-throughput mass spectrometry in over 5,200 participants, the machine learning model achieved an area under the curve of 0.850 in an independent external validation cohort of 545 patients. At a pre-specified rule-out threshold, the model demonstrated a sensitivity of 93.1% and a negative predictive value of 89.0% in the outpatient pulmonary medicine subgroup, offering a highly sensitive, non-invasive method to rule out malignancy and avoid unnecessary biopsies. Once a diagnosis of non-metastatic non-small-cell lung cancer is made, navigating the complex multidisciplinary treatment landscape is challenging. To address this, an international consensus statement published in the Journal of Thoracic Oncology gathered 89 thoracic oncology experts to evaluate 96 clinical scenarios [10]. The consensus strongly endorsed routine FDG PET-CT for staging, histologic confirmation of suspicious mediastinal nodes, reflex PD-L1 and DNA-based next-generation sequencing at diagnosis, and consolidation durvalumab after definitive chemoradiotherapy in unresectable stage II to III disease, regardless of PD-L1 expression. However, controversies persist, with no consensus reached on the routine use of brain MRI in stage I disease, mediastinal restaging after induction, routine RNA-based testing, or using circulating tumor DNA to guide perioperative decisions.

Finally, we shift to the intensive care unit to examine mechanical ventilation practices. A retrospective cohort study in Respiratory Medicine evaluated the impact of dual targeting during volume control ventilation [8]. Dual targeting is a ventilator feature designed to improve patient comfort by augmenting flow in response to patient demand; however, this can lead to larger tidal volumes than intended. Among 274 medical ICU patients, those ventilated with dual targeting were more than twice as likely to receive an average tidal volume exceeding 8 milliliters per kilogram of ideal body weight during the first 48 hours of intubation, with a rate of 26.1% compared to 12.5% in the control group. Although there were no significant differences in downstream patient outcomes such as ventilator-free days or mortality, this study serves as an important warning that dual targeting can quietly deliver non-lung-protective volumes, requiring close clinician monitoring.

If you only have time for one paper this week, make it the multicenter cohort study by Choi and colleagues in Chest on the prognostic impact of a single moderate COPD exacerbation [5]. This paper provides the critical, long-term validation needed to support the major GOLD 2026 guideline shift, proving that a single moderate exacerbation is a powerful predictor of future severe events and long-term mortality, and demonstrating that the updated risk classification significantly improves our ability to identify high-risk patients in daily practice.

Here are the key takeaways from this week in Pulmonary: First, a single moderate COPD exacerbation is not a minor event; it independently predicts future severe exacerbations and a more than threefold increase in respiratory mortality, validating the GOLD 2026 Group E classification [5]. Second, adding low-level emphysema on low-dose computed tomography to spirometry-defined obstructive lung disease more than triples long-term mortality risk, emphasizing the need to look for joint structural and functional defects [9]. Third, de-escalating maintenance macrolide therapy during summer months is not non-inferior to continuation and leads to earlier and more frequent exacerbations [2]. Fourth, in patients with pulmonary fibrosis, nerandomilast at 18 milligrams twice daily significantly reduces the risk of death by 43%, demonstrating a clear, dose-dependent survival benefit [1]. Finally, when using volume-controlled mechanical ventilation, the dual targeting feature significantly increases the risk of delivering non-lung-protective tidal volumes exceeding 8 milliliters per kilogram of ideal body weight [8].

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.